The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

There is provided a compound which provides a semiconductor material. The compound is represented by General Formula (1)

##STR00001##

wherein Ar represents an aryl group which may have a substituent or a heteroaryl group which may have a substituent, and R.sup.1 represents an acyclic alkyl group having 1 to 20 carbon atoms wherein hydrogen atom in the alkyl group may be replaced by a halogeno group, a nitrile group or an aryl group, and CH.sub.2 in the alkyl group may be replaced by O, RC?CR, CO, OCO, COO, S, SO.sub.2, SO, NH, NR or C?C provided that, with respect to each of an oxygen atom, a sulfur atom and a nitrogen atom, the same atoms are not directly bonded to each other, wherein R represents an acyclic or cyclic alkyl group having 1 to 20 carbon atoms.

There is provided a compound which provides a semiconductor material. The compound is represented by General Formula (1)

##STR00001##

wherein Ar represents an aryl group which may have a substituent or a heteroaryl group which may have a substituent, and R.sup.1 represents an acyclic alkyl group having 1 to 20 carbon atoms wherein hydrogen atom in the alkyl group may be replaced by a halogeno group, a nitrile group or an aryl group, and CH.sub.2 in the alkyl group may be replaced by O, RC?CR, CO, OCO, COO, S, SO.sub.2, SO, NH, NR or C?C provided that, with respect to each of an oxygen atom, a sulfur atom and a nitrogen atom, the same atoms are not directly bonded to each other, wherein R represents an acyclic or cyclic alkyl group having 1 to 20 carbon atoms.

A compound having the formula (I):

##STR00001##

wherein: R.sup.1 is selected from the group consisting of: H, F, (C.sub.1-C.sub.6)alkoxy, and halo(C.sub.1-C.sub.6)alkyl; and R.sup.2 is an optionally substituted heteroaryl group, as well as processes for the preparation of the compound, and intermediate compounds.

A compound having the formula (I):

##STR00001##

wherein: R.sup.1 is selected from the group consisting of: H, F, (C.sub.1-C.sub.6)alkoxy, and halo(C.sub.1-C.sub.6)alkyl; and R.sup.2 is an optionally substituted heteroaryl group, as well as processes for the preparation of the compound, and intermediate compounds.

The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

The present application relates to phenanthrene compounds of a particular formula (I), their use in electronic devices, electronic devices comprising such phenanthrene compounds, as well as processes for the synthesis of such phenanthrene compounds.

The invention is directed to ruthenium-based metathesis catalysts of the Grubbs-Hoveyda type. The new 2-aryloxy-substituted ruthenium catalysts described herein reveal rapid initiation behavior. Further, the corresponding styrene-based precursor compounds are disclosed. The catalysts are prepared in a cross-metathesis reaction starting from styrene-based precursors which can be prepared in a cost-effective manner.

The new Grubbs-Hoveyda type catalysts are suitable to catalyze ring-closing metathesis (RCM), cross metathesis (CM) and ring-opening metathesis polymerization (ROMP). Low catalyst loadings are necessary to convert a wide range of substrates including more complex and critical substrates via metathesis reactions at low to moderate temperatures in high yields within short reaction times.

The invention is directed to ruthenium-based metathesis catalysts of the Grubbs-Hoveyda type. The new 2-aryloxy-substituted ruthenium catalysts described herein reveal rapid initiation behavior. Further, the corresponding styrene-based precursor compounds are disclosed. The catalysts are prepared in a cross-metathesis reaction starting from styrene-based precursors which can be prepared in a cost-effective manner.

The new Grubbs-Hoveyda type catalysts are suitable to catalyze ring-closing metathesis (RCM), cross metathesis (CM) and ring-opening metathesis polymerization (ROMP). Low catalyst loadings are necessary to convert a wide range of substrates including more complex and critical substrates via metathesis reactions at low to moderate temperatures in high yields within short reaction times.